euglena Co., Ltd. (2931) AI Stock Analysis

• Market Cap: ¥61.05B
• Dividend Yield: N/A
• Average Volume (3M): 602.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 2.53%
• EPS Growth: 58.67%
• Country: JP
• Employees: 897
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -0.38
• Shares Outstanding: 136,599,260
• 10 Day Avg. Volume: 712,190
• 30 Day Avg. Volume: 602,383
• PEG Ratio: 1.09
• Price to Book (P/B): 1.76
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 29.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥461.00
• Price Target Upside: 3.13% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ¥461.00 ▲(3.13% Upside)

Euglena Co., Ltd. is on a positive trajectory with improved revenue growth and cash flow management. However, profitability challenges and a negative P/E ratio weigh heavily on the stock's valuation. Technical indicators suggest a neutral trend, lacking strong momentum. The absence of earnings call data and corporate events limits additional insights.

euglena Co., Ltd. Business Overview & Revenue Model

Company Description

Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae. It operates through Healthcare Business and Energy/Environment Business segments. The company also manufactures and sells foods and cosmetics using euglena. In addition, it offers health foods, beverages, confectionery, and sports food products. Further, the company develops biofuel technology and environmental related technology for microalgae; and invests in biotechnology related business. It distributes its products at convenience stores, drugstores, supermarkets, beauty salons, and variety shops. The company was incorporated in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Euglena Co., Ltd. generates revenue through multiple streams, primarily by selling dietary supplements and functional foods that incorporate Euglena as a key ingredient. The company has developed a range of products targeting health-conscious consumers, including capsules, powders, and fortified foods that emphasize the nutritional benefits of Euglena, such as its high protein and vitamin content. Additionally, Euglena Co., Ltd. earns income from its cosmetics division, where it offers skincare products utilizing the antioxidant properties of Euglena. The company may also engage in partnerships with other firms in the food, health, and beauty industries to expand its product offerings and market reach. Furthermore, the company invests in research and development to innovate new applications for Euglena and enhance its existing products, which can contribute to long-term revenue growth.

euglena Co., Ltd. Financial Statement Overview

Summary

Euglena Co., Ltd. is showing signs of recovery with improved revenue growth and cash flow management. However, profitability and return on equity remain challenges. The balance sheet reflects a healthier debt position, but further efforts are needed to enhance shareholder returns.

Income Statement

Euglena Co., Ltd. has shown a modest revenue growth rate of 2.44% in the latest year, indicating a positive trend in sales. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -1.37% and a low EBIT margin of 0.36%. The gross profit margin remains strong at 69.86%, suggesting efficient production processes. Despite improvements, the company needs to address its net losses to enhance overall financial health.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.82, indicating a more balanced capital structure compared to previous years. However, the return on equity remains negative at -2.05%, reflecting ongoing challenges in generating returns for shareholders. The equity ratio stands at 43.28%, which is a positive indicator of financial stability. Continued focus on reducing debt and improving profitability is essential for long-term growth.

Cash Flow

Euglena Co., Ltd. has demonstrated a significant improvement in free cash flow growth, with a 55.66% increase, highlighting better cash management. The operating cash flow to net income ratio of 0.21 indicates that the company is generating cash from operations, albeit at a moderate level. The free cash flow to net income ratio of 0.72 suggests that the company is effectively converting its earnings into cash, which is a positive sign for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2019	Dec 2018
Income Statement
Total Revenue	48.88B	47.62B	46.48B	44.39B	13.97B	15.17B
Gross Profit	34.18B	33.27B	31.77B	31.00B	9.96B	10.95B
EBITDA	5.38B	3.77B	1.34B	676.00M	-6.11B	-324.72M
Net Income	-352.50M	-650.00M	-2.65B	-2.68B	-9.80B	-1.25B
Balance Sheet
Total Assets	69.09B	73.26B	59.62B	57.27B	17.20B	21.84B
Cash, Cash Equivalents and Short-Term Investments	18.54B	20.63B	15.79B	9.95B	7.83B	4.43B
Total Debt	22.66B	25.92B	25.07B	22.22B	3.66B	3.85B
Total Liabilities	37.39B	41.14B	39.41B	37.92B	6.37B	5.93B
Stockholders Equity	30.59B	31.70B	20.21B	19.35B	10.83B	15.90B
Cash Flow
Free Cash Flow	2.41B	1.91B	-35.00M	428.00M	-289.40M	-4.50B
Operating Cash Flow	2.66B	2.65B	658.00M	924.00M	1.09B	-1.24B
Investing Cash Flow	-7.63B	-7.99B	-646.00M	1.23B	-1.44B	-3.89B
Financing Cash Flow	-992.00M	-485.00M	5.83B	-2.99B	2.71B	2.32B

euglena Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 447.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Negative. The current price of 447 is below the 20-day moving average (MA) of 450.45, below the 50-day MA of 464.62, and below the 200-day MA of 449.32, indicating a bearish trend. The MACD of -2.60 indicates Negative momentum. The RSI at 44.12 is Neutral, neither overbought nor oversold. The STOCH value of 30.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2931.

euglena Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4923	73 Outperform	¥38.55B	26.96	―	1.53%	6.10%	13.84%
4928	65 Neutral	¥146.53B	19.27	―	5.24%	-1.63%	1.81%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2931	54 Neutral	¥61.05B	―	―	―	2.53%	58.67%